Blackstone Life Sciences — 2024 Investments
1 investments dated 2024 · listed companies and verified rows first · show all
AvenCellavencell.comin𝕏Oct 2024 · $112M✓ verified
AvenCell Therapeutics develops next-generation cell therapies for hard-to-treat cancers, including solid tumors, combining switchable universal CAR-T technology with a CRISPR/Cas9-based allogeneic platform.
BiotechLongevityMedical Devices
Andrew Schiermeier(Chief Executive Officer)in
Co-investorsNovo HoldingsEight Roads VenturesF-Prime CapitalNYBC Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.